Clinical use of high sensitivity C-reactive protein for the prediction of adverse cardiovascular events

High-sensitivity C-reactive protein evaluation has recently been endorsed by the Centers for Disease Control and Prevention and by the American Heart Association to be used in conjunction with lipid evaluation as part of global risk prediction. Emerging evidence further suggests that high-sensitivity C-reactive protein can be used to target pharmacologic and lifestyle interventions designed to prevent first as well as recurrent cardiovascular events.